A great deal of progress has been made in the treatment of rheumatic diseases—from glucocorticoid use to the advent of biologic therapies. Gerd Burmester, MD, discussed this progress and the impact of biologics in this year’s Phillip Hench, MD, Memorial Lecture.
In case you missed it, on Nov. 20, the Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…
Implementation of rate increases for evaluation and management services and other changes bring big updates to many Current Procedural Terminology codes.
This ACR Convergence session discussed how recent advances in single-cell technologies are being used in rheumatic disease research.
In this ACR Convergence session, Jason R. Kolfenbach, MD, & John H. Stone, MD, MPH, shared clinical insights about rheumatic diseases.
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
ACR CONVERGENCE 2020—In her ARP keynote address on Friday, Nov. 6, Empowering Patients to Make an Impact on the Future of Healthcare, Jen Horonjeff, PhD, described a study in which researchers gathered data on pain and activity level among arthritis patients. In her view, the study provided a cautionary tale. Researchers expected the study subjects…
Researchers found half of patients taking the biosimilar infliximab-dyyb (Inflectra) remained highly adherent to medication use after 12 months.
As the COVID-19 pandemic stretches on, many clinicians are thinking about the lessons they’ve learned. Chris Phillips, MD, says rheumatology practices can no longer take their financial health for granted and flexibility is key.
In rural America, where rheumatology offices are fewer and farther between, the expansion of telemedicine has been a boon during the COVID-19 pandemic. However, lab closures and reduced hospital services have made monitoring patients’ medications more challenging.